Fig. 1.

Flow cytometric profiling of tumour dissociates. a) Schematic of the study design. b) Percentage of melanoma (CD45−/SOX10+), CD4+ (CD45+/CD4+) and CD8+ (CD45+CD8+) T cells in tumour dissociates of patients with melanoma (n = 5, treatment naive, NAIVE, blue; n = 5, progressed on PD-1-based therapy, IO PROG, red) following treatment with DMSO control or combination BRAF/MEK inhibitors dabrafenib and trametinib (DT, 10 nM and 1 nM, respectively). Percentages shown as a proportion of live viable cells in the samples. Cell frequencies for each sample are shown in Supplementary Table S2 and gating strategy of cells shown in Supplementary Figure S13. c) Boxplots showing fold change in phosphorylated S6 and Ki67 levels (median fluorescence intensity (MFI) of DMSO control/MFI DT) in NAIVE (blue) and IO PROG (red) tumour dissociates. Dotted line indicates a 1.5-fold difference. Data comparison between DMSO and DT performed using paired t-test while comparison between IO PROG and NAIVE performed using unpaired t-test; ns, not significant.